XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2018
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of estimated useful lives of property, plant and equipment

 

 

 

 

Production equipment

    

3 to 13 years

Office furniture, fixtures, and equipment

 

3 to 10 years

Buildings

 

39 years

Building improvements

 

15 years

 

Schedule of significant customers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

 

    

2018

    

2017

    

2016

 

Number of significant customers

 

 

 2

 

 

2

 

 

1

 

Aggregate dollar amount of net sales to significant customers

 

$

13.1 million

 

$

14.0  million

 

$

9.4  million

 

Percentage of net sales to significant customers

 

 

39.2

%

 

40.5

%

 

31.4

%

 

Schedule of disaggregated information of revenue recognized from contracts with customers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the year ended December 31, 2018:

 

    

 

 

    

Blood 

    

 

 

    

 

 

    

 

 

 

 

 

 

 

Collection 

 

EasyPoint® 

 

Other 

 

Total Product

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

 Sales

U.S. sales

 

$

23,803,483

 

$

1,365,936

 

$

3,401,389

 

$

75,766

 

$

28,646,574

North and South America sales (excluding U.S.)

 

 

3,521,823

 

 

8,805

 

 

252

 

 

66,564

 

 

3,597,444

Other international sales

 

 

940,740

 

 

48,101

 

 

11,768

 

 

30,075

 

 

1,030,684

Total

 

$

28,266,046

 

$

1,422,842

 

$

3,413,409

 

$

172,405

 

$

33,274,702

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the year ended December 31, 2017:

 

    

 

 

    

Blood 

    

 

 

    

 

 

    

 

 

 

 

 

 

 

Collection

 

EasyPoint® 

 

Other 

 

Total Product 

Geographic Segment

 

Syringes

 

 Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

23,794,258

 

$

1,098,667

 

$

2,065,777

 

$

57,010

 

$

27,015,712

North and South America sales (excluding U.S.)

 

 

6,182,952

 

 

3,859

 

 

 —

 

 

193,934

 

 

6,380,745

Other international sales

 

 

1,032,508

 

 

43,473

 

 

 —

 

 

21,400

 

 

1,097,381

Total

 

$

31,009,718

 

$

1,145,999

 

$

2,065,777

 

$

272,344

 

$

34,493,838

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the year ended December 31, 2016:

 

    

 

 

    

Blood 

    

 

 

    

 

 

    

 

 

 

 

 

 

 

Collection 

 

EasyPoint® 

 

Other 

 

Total Product 

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

24,349,061

 

$

571,242

 

$

1,339,386

 

$

48,557

 

$

26,308,246

North and South America sales (excluding U.S.)

 

 

2,643,366

 

 

2,778

 

 

 —

 

 

95,374

 

 

2,741,518

Other international sales

 

 

744,636

 

 

16,834

 

 

 —

 

 

15,402

 

 

776,872

Total

 

$

27,737,063

 

$

590,854

 

$

1,339,386

 

$

159,333

 

$

29,826,636

 

Schedule of earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

    

2018

    

2017

    

2016

Net loss

 

$

(1,339,943)

 

$

(3,736,038)

 

$

(3,694,907)

Preferred dividend requirements

 

 

(704,996)

 

 

(704,996)

 

 

(704,996)

Loss applicable to common shareholders

 

$

(2,044,939)

 

$

(4,441,034)

 

$

(4,399,903)

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

32,666,454

 

 

31,958,121

 

 

29,354,437

Weighted average common and common equivalent shares outstanding - assuming dilution

 

 

32,666,454

 

 

31,958,121

 

 

29,354,437

Basic loss per share

 

$

(0.06)

 

$

(0.14)

 

$

(0.15)

Diluted loss per share

 

$

(0.06)

 

$

(0.14)

 

$

(0.15)

 

Schedule of share-based compensation costs

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

    

2018

    

2017

    

2016

Cost of sales

 

$

 —

 

$

272,811

 

$

141,782

Sales and marketing

 

 

 —

 

 

143,255

 

 

77,583

Research and development

 

 

 —

 

 

45,174

 

 

23,623

General and administrative

 

 

 —

 

 

210,983

 

 

144,738

 

 

$

 —

 

$

672,223

 

$

387,726